![Antibodies | Free Full-Text | Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence Antibodies | Free Full-Text | Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence](https://pub.mdpi-res.com/antibodies/antibodies-09-00024/article_deploy/html/images/antibodies-09-00024-g001.png?1592563096)
Antibodies | Free Full-Text | Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence
A newer immunoglobulin intravenous (IGIV) – Gammagard® liquid 10%: Evaluation of efficacy, safety, tolerability and impact on
GAMMAGARD S/D [Immune Globulin Intravenous (Human)] IgA less than 1 microgram per mL in a 5% Solution
![These highlights do not include all the information needed to use GAMMAGARD S/D safely and effectively. See full prescribing information for GAMMAGARD S/D GAMMAGARD S/D, Immune Globulin Intravenous (Human)IgA less than 1 These highlights do not include all the information needed to use GAMMAGARD S/D safely and effectively. See full prescribing information for GAMMAGARD S/D GAMMAGARD S/D, Immune Globulin Intravenous (Human)IgA less than 1](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=gammagard-13.jpg&id=555419)